Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1 Meeting Abstract
| Authors: | Balar, A. V.; Galsky, M. D.; Loriot, Y.; Dawson, N. A.; Necchi, A.; Srinivas, S.; Joseph, R. W.; Vaishampayan, U. N.; Sridhar, S. S.; Quinn, D. I.; Drakaki, A.; Duran, I.; Rosenberg, J. E.; Powles, T.; Hoffman-Censits, J. H.; Cui, N.; Mariathasan, S.; Thastrom, A. C.; Abidoye, O. O.; Bajorin, D. F. |
| Abstract Title: | Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1 |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 18 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-06-20 |
| Start Page: | 751s |
| Language: | English |
| ACCESSION: | WOS:000443264100015 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2016.34.18_suppl.LBA4500 |
| Notes: | Meeting Abstract: LBA4500 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work